Tag: PCI
TCT 2019: Apixaban plus a P2Y12 inhibitor is the optimal strategy...
A prespecified analysis of data from the AUGUSTUS study, released at late-breaking session at the Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2019; 25–29 September,...
ESC 2017: Case builds for dropping aspirin from triple therapy in...
The RE-DUAL PCI trial indicates that dual therapy with the non-vitamin K antagonist oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim)—and not aspirin—and a P2Y12 inhibitor...
AHA 2016: Low-dose rivaroxaban reduces clinically significant bleeding in PCI patients...
Two drug regimens involving low doses of rivaroxaban (Xarelto, Bayer)—one with a 15mg once daily dose of the drug and a P2Y12 inhibitor and...